Biocon's Shaw on M&A Strategy

The transcript covers a discussion on a significant deal, addressing concerns about debt levels and market impact. It explores the commercialization of complex drugs, FDA inspection delays, and Biocon Biologics' IPO strategy. The genomic revolution in India and the company's positioning are highlighted, along with the relevance of vaccine production and supply chain challenges. Finally, it discusses India's capabilities in mRNA technology.

What opportunities does the speaker see in the genomic arena post-pandemic?

How is the Indian economy being impacted by supply chain disruptions and inflation?

What are the current capabilities of India in developing mRNA technology?